_MEMBER_data_imp_1 - 94.0-96.0,_MEMBER_data_imp_1 - 96.0-98.0,_MEMBER_data_imp_1 - 98.0-100.0,_LogP_data_imp_1 - 94.0-96.0,_LogP_data_imp_1 - 96.0-98.0,_LogP_data_imp_1 - 98.0-100.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-2.2,-3.1,-3.1,GO:0045596,negative regulation of cell differentiation,M111,3,0
1,1,1,-2.3,-3.4,-4,GO:0140747,regulation of ncRNA transcription,M111,3,0
1,1,1,-2.4,-2.8,-3.3,R-HSA-112316,Neuronal System,M111,3,0
1,1,1,-2.4,-4,-2.7,GO:0007420,brain development,M111,3,0
1,1,1,-2.5,-3.4,-2.8,GO:0060322,head development,M111,3,0
1,1,1,-2.5,-2.2,-2.2,GO:0007167,enzyme-linked receptor protein signaling pathway,M111,3,0
1,1,1,-2,-2.5,-5.4,GO:0008283,cell population proliferation,M111,3,0
1,1,1,-2.2,-2.9,-2.6,GO:0071407,cellular response to organic cyclic compound,M111,3,0
1,1,1,-3.5,-2.1,-4,GO:1901699,cellular response to nitrogen compound,M111,3,0
1,1,1,-2.2,-2.6,-4.1,GO:0098609,cell-cell adhesion,M111,3,0
1,1,1,-2.4,-3.1,-2.8,GO:0061061,muscle structure development,M111,3,0
1,1,1,-2.9,-2.1,-3.4,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M111,3,0
1,1,0,-2,-2.7,0,hsa05231,Choline metabolism in cancer,M110,2,0
0,1,1,0,-3,-3.7,GO:0007423,sensory organ development,M011,2,0
1,1,0,-2.9,-4.5,0,GO:1904018,positive regulation of vasculature development,M110,2,0
1,0,1,-2.4,0,-3.4,GO:0009792,embryo development ending in birth or egg hatching,M101,2,0
1,0,1,-2.6,0,-2.2,WP4172,PI3K Akt signaling pathway,M101,2,0
1,0,1,-3,0,-3,GO:0050867,positive regulation of cell activation,M101,2,0
1,0,1,-3.8,0,-3.8,GO:0046643,regulation of gamma-delta T cell activation,M101,2,0
0,1,1,0,-2,-2.1,M124,PID CXCR4 PATHWAY,M011,2,0
1,0,1,-2.7,0,-2.7,R-HSA-210500,Glutamate Neurotransmitter Release Cycle,M101,2,0
1,0,1,-2.4,0,-2.9,GO:0097305,response to alcohol,M101,2,0
1,0,1,-3.2,0,-3.2,GO:0045621,positive regulation of lymphocyte differentiation,M101,2,0
1,0,1,-3.2,0,-2.1,GO:0009611,response to wounding,M101,2,0
1,1,0,-2.3,-2.3,0,GO:0035239,tube morphogenesis,M110,2,0
1,0,1,-2.9,0,-4.1,GO:0045586,regulation of gamma-delta T cell differentiation,M101,2,0
1,0,1,-3.5,0,-3.5,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M101,2,0
0,1,1,0,-3.8,-3.8,GO:2000628,regulation of miRNA metabolic process,M011,2,0
0,1,1,0,-2.2,-2.7,WP2857,Mesodermal commitment pathway,M011,2,0
1,0,1,-4.1,0,-2.4,GO:1903037,regulation of leukocyte cell-cell adhesion,M101,2,0
1,1,0,-4.5,-2.5,0,GO:0010594,regulation of endothelial cell migration,M110,2,0
1,0,1,-2.2,0,-2.7,WP5083,Neuroinflammation and glutamatergic signaling,M101,2,0
1,0,1,-3.9,0,-2,GO:0030036,actin cytoskeleton organization,M101,2,0
1,1,0,-3.3,-2.1,0,GO:0045859,regulation of protein kinase activity,M110,2,0
1,1,0,-2.4,-3,0,M186,PID PDGFRB PATHWAY,M110,2,0
1,1,0,-3.3,-2.5,0,R-HSA-449147,Signaling by Interleukins,M110,2,0
1,1,0,-2.1,-2.1,0,GO:0030323,respiratory tube development,M110,2,0
1,0,1,-3.1,0,-3.1,GO:0045787,positive regulation of cell cycle,M101,2,0
0,1,1,0,-3.9,-3.3,hsa04550,Signaling pathways regulating pluripotency of stem cells,M011,2,0
0,1,1,0,-2.6,-2.3,GO:0001568,blood vessel development,M011,2,0
1,0,1,-2.9,0,-2.2,GO:0002696,positive regulation of leukocyte activation,M101,2,0
1,0,1,-2.8,0,-3.3,hsa04810,Regulation of actin cytoskeleton,M101,2,0
1,1,0,-3.7,-2,0,GO:0051347,positive regulation of transferase activity,M110,2,0
1,0,1,-2.8,0,-3.2,GO:0030097,hemopoiesis,M101,2,0
0,1,1,0,-2.6,-2.7,GO:0051216,cartilage development,M011,2,0
1,1,0,-2.1,-2.1,0,WP1539,Angiogenesis,M110,2,0
0,1,1,0,-2.1,-5.2,WP2064,Neural crest differentiation,M011,2,0
0,1,1,0,-2,-2,GO:0051146,striated muscle cell differentiation,M011,2,0
1,0,1,-2.5,0,-4,GO:1901653,cellular response to peptide,M101,2,0
0,1,1,0,-3.1,-3.1,WP3527,Pre implantation embryo,M011,2,0
1,0,1,-3,0,-3.4,GO:0001701,in utero embryonic development,M101,2,0
0,1,1,0,-2,-2,GO:0019082,viral protein processing,M011,2,0
1,0,1,-3.4,0,-3.4,GO:0045588,positive regulation of gamma-delta T cell differentiation,M101,2,0
0,1,1,0,-2.4,-2.9,GO:0050803,regulation of synapse structure or activity,M011,2,0
0,1,1,0,-2.8,-2.4,GO:0032870,cellular response to hormone stimulus,M011,2,0
1,1,0,-2.4,-2.4,0,GO:0032835,glomerulus development,M110,2,0
1,0,1,-2.2,0,-2.2,GO:0042098,T cell proliferation,M101,2,0
1,0,1,-2.9,0,-2.9,GO:0090068,positive regulation of cell cycle process,M101,2,0
1,1,0,-4,-2.3,0,hsa05207,Chemical carcinogenesis - receptor activation,M110,2,0
1,1,0,-3,-2.9,0,GO:0032989,cellular anatomical entity morphogenesis,M110,2,0
0,1,1,0,-2.4,-2.9,GO:0050807,regulation of synapse organization,M011,2,0
1,0,1,-2.2,0,-2.2,GO:0046629,gamma-delta T cell activation,M101,2,0
1,0,1,-3.3,0,-4.2,GO:0071417,cellular response to organonitrogen compound,M101,2,0
0,1,1,0,-3.5,-2.9,GO:0002062,chondrocyte differentiation,M011,2,0
1,0,1,-2.4,0,-3.7,GO:0001775,cell activation,M101,2,0
1,0,1,-3,0,-2.3,GO:1903706,regulation of hemopoiesis,M101,2,0
1,1,0,-3.1,-4.1,0,GO:0045766,positive regulation of angiogenesis,M110,2,0
1,1,0,-2.1,-2.4,0,GO:0001525,angiogenesis,M110,2,0
1,0,1,-2.3,0,-2.7,GO:1902107,positive regulation of leukocyte differentiation,M101,2,0
1,1,0,-3.9,-2.6,0,hsa04630,JAK-STAT signaling pathway,M110,2,0
0,1,1,0,-3.5,-4.2,GO:1902893,regulation of miRNA transcription,M011,2,0
0,1,1,0,-2.4,-2.2,GO:0001944,vasculature development,M011,2,0
0,1,1,0,-2.4,-2.8,GO:0007507,heart development,M011,2,0
1,0,1,-3.1,0,-2.5,GO:0045582,positive regulation of T cell differentiation,M101,2,0
1,0,1,-2.3,0,-2.7,GO:1903708,positive regulation of hemopoiesis,M101,2,0
1,1,0,-2.2,-2.5,0,GO:0009725,response to hormone,M110,2,0
1,1,0,-2.1,-2.1,0,WP5087,Pleural mesothelioma,M110,2,0
1,1,0,-5,-3.7,0,hsa05200,Pathways in cancer,M110,2,0
1,1,0,-4.1,-2.1,0,GO:0045860,positive regulation of protein kinase activity,M110,2,0
1,1,0,-2.4,-2.4,0,GO:0072239,metanephric glomerulus vasculature development,M110,2,0
0,1,1,0,-3.5,-2.7,GO:0050678,regulation of epithelial cell proliferation,M011,2,0
1,0,1,-5.3,0,-2.4,GO:0050865,regulation of cell activation,M101,2,0
1,0,1,-3.9,0,-2.5,GO:0022407,regulation of cell-cell adhesion,M101,2,0
1,0,1,-2.9,0,-2.5,GO:0045619,regulation of lymphocyte differentiation,M101,2,0
0,1,1,0,-2.9,-2.5,GO:0061448,connective tissue development,M011,2,0
1,0,1,-4.2,0,-3.3,M28,PID IL4 2PATHWAY,M101,2,0
1,1,0,-2.7,-2.7,0,GO:0072091,regulation of stem cell proliferation,M110,2,0
0,1,1,0,-2.6,-3.7,GO:0071363,cellular response to growth factor stimulus,M011,2,0
1,0,1,-4.4,0,-3.1,GO:0046645,positive regulation of gamma-delta T cell activation,M101,2,0
1,0,1,-2.2,0,-3.6,GO:0043009,chordate embryonic development,M101,2,0
1,1,0,-3.1,-2.2,0,hsa04510,Focal adhesion,M110,2,0
1,0,1,-3.1,0,-2.6,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M101,2,0
0,1,1,0,-2,-2.1,GO:1901655,cellular response to ketone,M011,2,0
1,0,1,-2.3,0,-2.3,GO:1902895,positive regulation of miRNA transcription,M101,2,0
1,1,0,-4,-2.6,0,GO:0010632,regulation of epithelial cell migration,M110,2,0
0,1,1,0,-3.2,-3.7,GO:0070848,response to growth factor,M011,2,0
1,0,1,-2.3,0,-3,GO:0048568,embryonic organ development,M101,2,0
0,0,1,0,0,-2.3,GO:0007159,leukocyte cell-cell adhesion,M001,1,0
0,0,1,0,0,-2.5,M195,PID CMYB PATHWAY,M001,1,0
0,0,1,0,0,-2.9,M167,PID AP1 PATHWAY,M001,1,0
0,0,1,0,0,-2.2,GO:0019233,sensory perception of pain,M001,1,0
1,0,0,-2.1,0,0,R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,M100,1,0
1,0,0,-2.5,0,0,GO:0046634,regulation of alpha-beta T cell activation,M100,1,0
0,1,0,0,-4.3,0,GO:1902894,negative regulation of miRNA transcription,M010,1,0
1,0,0,-3.2,0,0,WP4262,Breast cancer pathway,M100,1,0
0,0,1,0,0,-3.5,GO:0021700,developmental maturation,M001,1,0
1,0,0,-2.7,0,0,R-HSA-8985947,Interleukin-9 signaling,M100,1,0
0,0,1,0,0,-3.1,GO:0060710,chorio-allantoic fusion,M001,1,0
1,0,0,-2,0,0,R-HSA-4085001,Sialic acid metabolism,M100,1,0
1,0,0,-2.5,0,0,GO:0032943,mononuclear cell proliferation,M100,1,0
1,0,0,-2.7,0,0,R-HSA-1266695,Interleukin-7 signaling,M100,1,0
0,0,1,0,0,-2.7,GO:0030098,lymphocyte differentiation,M001,1,0
0,0,1,0,0,-2.2,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M001,1,0
1,0,0,-3.2,0,0,WP4806,EGFR tyrosine kinase inhibitor resistance,M100,1,0
1,0,0,-2.2,0,0,GO:0070328,triglyceride homeostasis,M100,1,0
0,0,1,0,0,-2.1,GO:0048704,embryonic skeletal system morphogenesis,M001,1,0
0,0,1,0,0,-2.3,GO:0006887,exocytosis,M001,1,0
1,0,0,-2.1,0,0,M5885,NABA MATRISOME ASSOCIATED,M100,1,0
1,0,0,-2.4,0,0,GO:0010799,regulation of peptidyl-threonine phosphorylation,M100,1,0
0,1,0,0,-2.7,0,GO:0043254,regulation of protein-containing complex assembly,M010,1,0
0,1,0,0,-3,0,GO:0090263,positive regulation of canonical Wnt signaling pathway,M010,1,0
0,1,0,0,-3.1,0,GO:0071732,cellular response to nitric oxide,M010,1,0
1,0,0,-2.2,0,0,WP3888,VEGFA VEGFR2 signaling,M100,1,0
1,0,0,-2.1,0,0,GO:0072001,renal system development,M100,1,0
1,0,0,-3.4,0,0,GO:0042102,positive regulation of T cell proliferation,M100,1,0
0,1,0,0,-2,0,WP3630,NAD metabolism sirtuins and aging,M010,1,0
0,0,1,0,0,-4.6,GO:0007268,chemical synaptic transmission,M001,1,0
1,0,0,-3.4,0,0,GO:0031401,positive regulation of protein modification process,M100,1,0
1,0,0,-2.1,0,0,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M100,1,0
0,0,1,0,0,-2.7,GO:0010614,negative regulation of cardiac muscle hypertrophy,M001,1,0
0,1,0,0,-2.4,0,GO:0061049,cell growth involved in cardiac muscle cell development,M010,1,0
0,1,0,0,-2.5,0,GO:0009165,nucleotide biosynthetic process,M010,1,0
0,1,0,0,-2.7,0,hsa00601,Glycosphingolipid biosynthesis - lacto and neolacto series,M010,1,0
1,0,0,-3.1,0,0,GO:0043380,regulation of memory T cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0030522,intracellular receptor signaling pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0061045,negative regulation of wound healing,M100,1,0
0,0,1,0,0,-2.4,GO:0007213,G protein-coupled acetylcholine receptor signaling pathway,M001,1,0
1,0,0,-2.2,0,0,WP205,IL 7 signaling pathway,M100,1,0
1,0,0,-2,0,0,M1529,SA G1 AND S PHASES,M100,1,0
1,0,0,-3.4,0,0,WP22,IL 9 signaling pathway,M100,1,0
1,0,0,-2.6,0,0,R-HSA-5653656,Vesicle-mediated transport,M100,1,0
1,0,0,-3.4,0,0,GO:0090130,tissue migration,M100,1,0
1,0,0,-2.7,0,0,GO:0043568,positive regulation of insulin-like growth factor receptor signaling pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0014897,striated muscle hypertrophy,M010,1,0
1,0,0,-3,0,0,GO:2000573,positive regulation of DNA biosynthetic process,M100,1,0
1,0,0,-4.4,0,0,GO:2000147,positive regulation of cell motility,M100,1,0
0,1,0,0,-2.1,0,WP363,Wnt signaling pathway,M010,1,0
1,0,0,-2.7,0,0,GO:0002698,negative regulation of immune effector process,M100,1,0
1,0,0,-2,0,0,GO:0061138,morphogenesis of a branching epithelium,M100,1,0
1,0,0,-2.8,0,0,hsa04659,Th17 cell differentiation,M100,1,0
0,0,1,0,0,-3,WP2032,Thyroid stimulating hormone TSH signaling pathway,M001,1,0
0,0,1,0,0,-2.7,GO:0015800,acidic amino acid transport,M001,1,0
0,1,0,0,-2.2,0,GO:0021780,glial cell fate specification,M010,1,0
0,1,0,0,-3.5,0,GO:0045576,mast cell activation,M010,1,0
0,0,1,0,0,-2.1,R-HSA-112310,Neurotransmitter release cycle,M001,1,0
0,1,0,0,-2.2,0,GO:0001933,negative regulation of protein phosphorylation,M010,1,0
1,0,0,-2.2,0,0,GO:0022602,ovulation cycle process,M100,1,0
1,0,0,-3.2,0,0,GO:0061351,neural precursor cell proliferation,M100,1,0
0,1,0,0,-2.7,0,GO:0043547,positive regulation of GTPase activity,M010,1,0
1,0,0,-3.1,0,0,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M100,1,0
1,0,0,-2.5,0,0,GO:0050866,negative regulation of cell activation,M100,1,0
0,0,1,0,0,-3.1,GO:0032763,regulation of mast cell cytokine production,M001,1,0
0,1,0,0,-2,0,GO:0001936,regulation of endothelial cell proliferation,M010,1,0
0,1,0,0,-3.1,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M010,1,0
1,0,0,-5.6,0,0,GO:0045937,positive regulation of phosphate metabolic process,M100,1,0
1,0,0,-2,0,0,GO:0010657,muscle cell apoptotic process,M100,1,0
0,0,1,0,0,-2.2,GO:0002320,lymphoid progenitor cell differentiation,M001,1,0
0,1,0,0,-2.1,0,GO:2000736,regulation of stem cell differentiation,M010,1,0
0,0,1,0,0,-2.9,GO:0010463,mesenchymal cell proliferation,M001,1,0
0,1,0,0,-2.4,0,GO:0051046,regulation of secretion,M010,1,0
0,1,0,0,-2.2,0,WP5153,N glycan biosynthesis,M010,1,0
1,0,0,-3.5,0,0,GO:0050777,negative regulation of immune response,M100,1,0
1,0,0,-2.1,0,0,GO:0003281,ventricular septum development,M100,1,0
0,0,1,0,0,-2,GO:2000630,positive regulation of miRNA metabolic process,M001,1,0
1,0,0,-2.5,0,0,GO:0015697,quaternary ammonium group transport,M100,1,0
1,0,0,-3.1,0,0,GO:0051249,regulation of lymphocyte activation,M100,1,0
0,0,1,0,0,-3.1,GO:0003272,endocardial cushion formation,M001,1,0
1,0,0,-2.7,0,0,GO:0001542,ovulation from ovarian follicle,M100,1,0
0,0,1,0,0,-2.9,GO:0002639,positive regulation of immunoglobulin production,M001,1,0
1,0,0,-2.2,0,0,hsa04022,cGMP-PKG signaling pathway,M100,1,0
0,0,1,0,0,-2.7,GO:0098712,L-glutamate import across plasma membrane,M001,1,0
0,1,0,0,-2.5,0,GO:0043116,negative regulation of vascular permeability,M010,1,0
0,1,0,0,-2.6,0,GO:0016049,cell growth,M010,1,0
1,0,0,-2.1,0,0,WP2447,Amyotrophic lateral sclerosis ALS,M100,1,0
0,0,1,0,0,-2.7,GO:0045055,regulated exocytosis,M001,1,0
1,0,0,-2.4,0,0,GO:0071350,cellular response to interleukin-15,M100,1,0
0,0,1,0,0,-2.4,GO:0002262,myeloid cell homeostasis,M001,1,0
0,1,0,0,-3.1,0,WP3655,Hypothetical craniofacial development pathway,M010,1,0
0,0,1,0,0,-2.9,GO:0001818,negative regulation of cytokine production,M001,1,0
0,0,1,0,0,-2.5,GO:0050864,regulation of B cell activation,M001,1,0
0,1,0,0,-2.4,0,GO:0003298,physiological muscle hypertrophy,M010,1,0
1,0,0,-2.4,0,0,hsa04915,Estrogen signaling pathway,M100,1,0
0,1,0,0,-2.5,0,GO:0043255,regulation of carbohydrate biosynthetic process,M010,1,0
1,0,0,-2.4,0,0,GO:0007596,blood coagulation,M100,1,0
1,0,0,-2,0,0,GO:0060396,growth hormone receptor signaling pathway,M100,1,0
1,0,0,-2.9,0,0,GO:0070665,positive regulation of leukocyte proliferation,M100,1,0
1,0,0,-7.2,0,0,hsa04218,Cellular senescence,M100,1,0
0,0,1,0,0,-2.6,GO:0010453,regulation of cell fate commitment,M001,1,0
0,0,1,0,0,-2.5,hsa05202,Transcriptional misregulation in cancer,M001,1,0
0,0,1,0,0,-2.7,GO:0035249,"synaptic transmission, glutamatergic",M001,1,0
0,0,1,0,0,-2.7,M235,PID TCR CALCIUM PATHWAY,M001,1,0
0,1,0,0,-3.5,0,GO:0007409,axonogenesis,M010,1,0
0,1,0,0,-2,0,GO:0002088,lens development in camera-type eye,M010,1,0
0,1,0,0,-2.7,0,WP2895,Differentiation of white and brown adipocyte,M010,1,0
0,1,0,0,-2.2,0,GO:0090183,regulation of kidney development,M010,1,0
0,1,0,0,-3.7,0,GO:0031175,neuron projection development,M010,1,0
1,0,0,-2.4,0,0,WP314,Fas ligand pathway and stress induction of heat shock proteins,M100,1,0
1,0,0,-5.3,0,0,hsa05215,Prostate cancer,M100,1,0
0,0,1,0,0,-2.4,R-HSA-112315,Transmission across Chemical Synapses,M001,1,0
0,0,1,0,0,-2.4,M44,PID HIF2PATHWAY,M001,1,0
1,0,0,-3.2,0,0,WP3657,Hematopoietic stem cell gene regulation by GABP alpha beta complex,M100,1,0
1,0,0,-4.1,0,0,GO:0033674,positive regulation of kinase activity,M100,1,0
0,0,1,0,0,-3.5,GO:0050954,sensory perception of mechanical stimulus,M001,1,0
1,0,0,-2,0,0,GO:0003073,regulation of systemic arterial blood pressure,M100,1,0
1,0,0,-2.7,0,0,GO:0044770,cell cycle phase transition,M100,1,0
1,0,0,-2.2,0,0,GO:0070243,regulation of thymocyte apoptotic process,M100,1,0
1,0,0,-2.5,0,0,GO:0061919,process utilizing autophagic mechanism,M100,1,0
1,0,0,-2.3,0,0,GO:0033135,regulation of peptidyl-serine phosphorylation,M100,1,0
0,1,0,0,-2.4,0,GO:0045936,negative regulation of phosphate metabolic process,M010,1,0
1,0,0,-3,0,0,GO:0030029,actin filament-based process,M100,1,0
0,0,1,0,0,-2.7,GO:0060337,type I interferon-mediated signaling pathway,M001,1,0
1,0,0,-2.1,0,0,GO:0006897,endocytosis,M100,1,0
1,0,0,-4,0,0,GO:0001934,positive regulation of protein phosphorylation,M100,1,0
0,1,0,0,-2.1,0,WP2884,NRF2 pathway,M010,1,0
1,0,0,-3.4,0,0,hsa05166,Human T-cell leukemia virus 1 infection,M100,1,0
1,0,0,-2.2,0,0,GO:0098543,detection of other organism,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9009391,Extra-nuclear estrogen signaling,M100,1,0
0,0,1,0,0,-2,GO:0048469,cell maturation,M001,1,0
1,0,0,-3.4,0,0,M100,PID SHP2 PATHWAY,M100,1,0
0,0,1,0,0,-2.4,GO:0045830,positive regulation of isotype switching,M001,1,0
0,1,0,0,-2.6,0,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M010,1,0
0,0,1,0,0,-4.3,GO:0060348,bone development,M001,1,0
1,0,0,-2.3,0,0,GO:0003180,aortic valve morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0002715,regulation of natural killer cell mediated immunity,M100,1,0
1,0,0,-2.9,0,0,R-HSA-6804116,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,M100,1,0
0,0,1,0,0,-3.8,GO:0048821,erythrocyte development,M001,1,0
0,1,0,0,-2.9,0,GO:0002448,mast cell mediated immunity,M010,1,0
1,0,0,-3.3,0,0,hsa05224,Breast cancer,M100,1,0
1,0,0,-2.1,0,0,GO:0050691,regulation of defense response to virus by host,M100,1,0
0,0,1,0,0,-4.2,M60,PID NFAT TFPATHWAY,M001,1,0
0,0,1,0,0,-2.4,WP3971,OSX and miRNAs in tooth development,M001,1,0
1,0,0,-2.4,0,0,GO:0055013,cardiac muscle cell development,M100,1,0
0,0,1,0,0,-2.5,GO:0007188,adenylate cyclase-modulating G protein-coupled receptor signaling pathway,M001,1,0
1,0,0,-2.4,0,0,GO:0010757,negative regulation of plasminogen activation,M100,1,0
0,0,1,0,0,-2,GO:0043031,negative regulation of macrophage activation,M001,1,0
1,0,0,-2.5,0,0,GO:2000278,regulation of DNA biosynthetic process,M100,1,0
1,0,0,-2.2,0,0,M3686,SA REG CASCADE OF CYCLIN EXPR,M100,1,0
1,0,0,-2,0,0,GO:0014909,smooth muscle cell migration,M100,1,0
1,0,0,-2,0,0,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M100,1,0
1,0,0,-3.1,0,0,GO:0072104,glomerular capillary formation,M100,1,0
0,0,1,0,0,-2.3,hsa04024,cAMP signaling pathway,M001,1,0
0,1,0,0,-2.4,0,GO:0009756,carbohydrate mediated signaling,M010,1,0
1,0,0,-2.4,0,0,GO:0030728,ovulation,M100,1,0
0,0,1,0,0,-2.1,WP4808,Endochondral ossification with skeletal dysplasias,M001,1,0
0,0,1,0,0,-3.2,GO:0045931,positive regulation of mitotic cell cycle,M001,1,0
1,0,0,-2.1,0,0,GO:0070670,response to interleukin-4,M100,1,0
1,0,0,-2.3,0,0,GO:0002831,regulation of response to biotic stimulus,M100,1,0
1,0,0,-4.8,0,0,hsa05214,Glioma,M100,1,0
1,0,0,-3.7,0,0,GO:0031342,negative regulation of cell killing,M100,1,0
0,0,1,0,0,-2.9,GO:0045191,regulation of isotype switching,M001,1,0
1,0,0,-2.2,0,0,GO:0001763,morphogenesis of a branching structure,M100,1,0
0,0,1,0,0,-2.1,hsa04666,Fc gamma R-mediated phagocytosis,M001,1,0
1,0,0,-2.3,0,0,hsa04068,FoxO signaling pathway,M100,1,0
0,1,0,0,-3.4,0,GO:0000902,cell morphogenesis,M010,1,0
0,0,1,0,0,-3,GO:0051962,positive regulation of nervous system development,M001,1,0
1,0,0,-3,0,0,GO:2000178,negative regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2.7,0,0,GO:0030195,negative regulation of blood coagulation,M100,1,0
0,1,0,0,-3,0,WP23,B cell receptor signaling pathway,M010,1,0
0,1,0,0,-2,0,GO:0051223,regulation of protein transport,M010,1,0
1,0,0,-3.5,0,0,hsa01522,Endocrine resistance,M100,1,0
1,0,0,-2.3,0,0,GO:0002704,negative regulation of leukocyte mediated immunity,M100,1,0
0,1,0,0,-2.4,0,GO:0060986,endocrine hormone secretion,M010,1,0
1,0,0,-3.4,0,0,GO:0097435,supramolecular fiber organization,M100,1,0
0,1,0,0,-2.4,0,GO:0034762,regulation of transmembrane transport,M010,1,0
1,0,0,-3.2,0,0,GO:0002694,regulation of leukocyte activation,M100,1,0
1,0,0,-2.4,0,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M100,1,0
0,0,1,0,0,-2.1,GO:0031018,endocrine pancreas development,M001,1,0
1,0,0,-2.8,0,0,GO:0002697,regulation of immune effector process,M100,1,0
1,0,0,-2.1,0,0,GO:0043029,T cell homeostasis,M100,1,0
0,0,1,0,0,-2.4,GO:0060193,positive regulation of lipase activity,M001,1,0
1,0,0,-2,0,0,WP4685,Melanoma,M100,1,0
1,0,0,-2.9,0,0,GO:0050851,antigen receptor-mediated signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0007229,integrin-mediated signaling pathway,M100,1,0
1,0,0,-3.1,0,0,hsa05218,Melanoma,M100,1,0
1,0,0,-2.4,0,0,WP4658,Small cell lung cancer,M100,1,0
1,0,0,-2.8,0,0,WP304,Kit receptor signaling pathway,M100,1,0
1,0,0,-2.9,0,0,M122,PID IL2 1PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:0043087,regulation of GTPase activity,M010,1,0
1,0,0,-2.6,0,0,R-HSA-9607240,FLT3 Signaling,M100,1,0
1,0,0,-2.7,0,0,GO:0042492,gamma-delta T cell differentiation,M100,1,0
0,1,0,0,-2.5,0,GO:0014896,muscle hypertrophy,M010,1,0
0,0,1,0,0,-2.9,GO:0045579,positive regulation of B cell differentiation,M001,1,0
1,0,0,-2.7,0,0,GO:0050671,positive regulation of lymphocyte proliferation,M100,1,0
0,0,1,0,0,-2,GO:0097094,craniofacial suture morphogenesis,M001,1,0
1,0,0,-3.1,0,0,GO:0072103,glomerulus vasculature morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0002707,negative regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.2,0,0,R-HSA-4090294,SUMOylation of intracellular receptors,M100,1,0
1,0,0,-3.1,0,0,GO:0055001,muscle cell development,M100,1,0
0,0,1,0,0,-2.7,GO:0071357,cellular response to type I interferon,M001,1,0
1,0,0,-2.7,0,0,WP581,EPO receptor signaling,M100,1,0
0,1,0,0,-3.4,0,GO:0048858,cell projection morphogenesis,M010,1,0
0,1,0,0,-2.1,0,hsa04012,ErbB signaling pathway,M010,1,0
0,0,1,0,0,-2.1,WP474,Endochondral ossification,M001,1,0
0,0,1,0,0,-2.6,GO:0071695,anatomical structure maturation,M001,1,0
1,0,0,-3,0,0,GO:0060021,roof of mouth development,M100,1,0
0,0,1,0,0,-2.5,GO:0045661,regulation of myoblast differentiation,M001,1,0
0,1,0,0,-2.8,0,GO:0051147,regulation of muscle cell differentiation,M010,1,0
0,0,1,0,0,-2.4,GO:0042473,outer ear morphogenesis,M001,1,0
1,0,0,-2.1,0,0,M231,PID KIT PATHWAY,M100,1,0
0,0,1,0,0,-2.2,GO:1900274,regulation of phospholipase C activity,M001,1,0
1,0,0,-3.1,0,0,R-HSA-9020558,Interleukin-2 signaling,M100,1,0
0,1,0,0,-2.4,0,GO:0061140,lung secretory cell differentiation,M010,1,0
0,0,1,0,0,-2.2,hsa04020,Calcium signaling pathway,M001,1,0
1,0,0,-2.8,0,0,hsa05220,Chronic myeloid leukemia,M100,1,0
0,0,1,0,0,-2,GO:0048839,inner ear development,M001,1,0
1,0,0,-2.2,0,0,GO:0060707,trophoblast giant cell differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0031400,negative regulation of protein modification process,M010,1,0
0,0,1,0,0,-2.3,GO:0071773,cellular response to BMP stimulus,M001,1,0
0,0,1,0,0,-2.1,WP5102,Familial partial lipodystrophy,M001,1,0
0,0,1,0,0,-2.1,GO:0010976,positive regulation of neuron projection development,M001,1,0
0,0,1,0,0,-3.3,GO:0032869,cellular response to insulin stimulus,M001,1,0
0,0,1,0,0,-2.5,WP53,ID signaling pathway,M001,1,0
1,0,0,-2.7,0,0,GO:1900047,negative regulation of hemostasis,M100,1,0
0,0,1,0,0,-2.7,R-HSA-9012999,RHO GTPase cycle,M001,1,0
0,1,0,0,-2,0,hsa04650,Natural killer cell mediated cytotoxicity,M010,1,0
0,0,1,0,0,-2.1,GO:0048562,embryonic organ morphogenesis,M001,1,0
1,0,0,-2.7,0,0,WP2261,Glioblastoma signaling pathways,M100,1,0
1,0,0,-2.1,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.2,0,0,WP5180,DYRK1A involvement regarding cell proliferation in brain development,M100,1,0
1,0,0,-3.1,0,0,hsa04114,Oocyte meiosis,M100,1,0
0,0,1,0,0,-2.7,GO:0021846,cell proliferation in forebrain,M001,1,0
0,0,1,0,0,-2.8,GO:0010518,positive regulation of phospholipase activity,M001,1,0
0,0,1,0,0,-2.4,GO:0045646,regulation of erythrocyte differentiation,M001,1,0
0,1,0,0,-2.2,0,GO:2000271,positive regulation of fibroblast apoptotic process,M010,1,0
0,1,0,0,-2.6,0,M33,PID GLYPICAN 1PATHWAY,M010,1,0
0,0,1,0,0,-3,GO:1901890,positive regulation of cell junction assembly,M001,1,0
0,0,1,0,0,-2.2,GO:0003161,cardiac conduction system development,M001,1,0
0,0,1,0,0,-2,GO:0048705,skeletal system morphogenesis,M001,1,0
1,0,0,-3.2,0,0,GO:0032946,positive regulation of mononuclear cell proliferation,M100,1,0
0,1,0,0,-2.8,0,M285,PID HNF3A PATHWAY,M010,1,0
1,0,0,-3.4,0,0,GO:0031341,regulation of cell killing,M100,1,0
0,1,0,0,-2.7,0,GO:0071731,response to nitric oxide,M010,1,0
1,0,0,-2.1,0,0,GO:2000516,"positive regulation of CD4-positive, alpha-beta T cell activation",M100,1,0
0,0,1,0,0,-3,GO:0051963,regulation of synapse assembly,M001,1,0
0,1,0,0,-2.1,0,R-HSA-9772573,Late SARS-CoV-2 Infection Events,M010,1,0
1,0,0,-4,0,0,GO:0032102,negative regulation of response to external stimulus,M100,1,0
0,0,1,0,0,-2.9,GO:0035113,embryonic appendage morphogenesis,M001,1,0
1,0,0,-2.3,0,0,GO:0061437,renal system vasculature development,M100,1,0
1,0,0,-2.4,0,0,GO:0032516,positive regulation of phosphoprotein phosphatase activity,M100,1,0
0,0,1,0,0,-2.5,GO:0042476,odontogenesis,M001,1,0
0,0,1,0,0,-2.3,GO:0051960,regulation of nervous system development,M001,1,0
1,0,0,-2.2,0,0,M180,PID HIF1A PATHWAY,M100,1,0
0,1,0,0,-2.7,0,GO:0060487,lung epithelial cell differentiation,M010,1,0
1,0,0,-2.7,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M100,1,0
1,0,0,-2.4,0,0,hsa04151,PI3K-Akt signaling pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0036092,phosphatidylinositol-3-phosphate biosynthetic process,M010,1,0
0,1,0,0,-2.5,0,GO:0044092,negative regulation of molecular function,M010,1,0
1,0,0,-2.4,0,0,hsa04921,Oxytocin signaling pathway,M100,1,0
1,0,0,-2.1,0,0,WP366,TGF beta signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0140694,non-membrane-bounded organelle assembly,M100,1,0
1,0,0,-2.2,0,0,GO:0046641,positive regulation of alpha-beta T cell proliferation,M100,1,0
1,0,0,-2.4,0,0,GO:0035723,interleukin-15-mediated signaling pathway,M100,1,0
0,1,0,0,-5.1,0,GO:1901342,regulation of vasculature development,M010,1,0
1,0,0,-3,0,0,GO:0051251,positive regulation of lymphocyte activation,M100,1,0
0,1,0,0,-2.1,0,GO:0043303,mast cell degranulation,M010,1,0
1,0,0,-2,0,0,GO:0071361,cellular response to ethanol,M100,1,0
1,0,0,-2.7,0,0,GO:0001915,negative regulation of T cell mediated cytotoxicity,M100,1,0
0,0,1,0,0,-3.4,GO:0060191,regulation of lipase activity,M001,1,0
1,0,0,-2,0,0,GO:0010658,striated muscle cell apoptotic process,M100,1,0
0,0,1,0,0,-2.5,GO:0003197,endocardial cushion development,M001,1,0
1,0,0,-3.1,0,0,GO:0033138,positive regulation of peptidyl-serine phosphorylation,M100,1,0
0,0,1,0,0,-2.2,GO:0035107,appendage morphogenesis,M001,1,0
0,0,1,0,0,-2,GO:0003013,circulatory system process,M001,1,0
1,0,0,-2.2,0,0,R-HSA-1251985,Nuclear signaling by ERBB4,M100,1,0
0,1,0,0,-3,0,WP4331,Neovascularisation processes,M010,1,0
0,0,1,0,0,-5,GO:0061515,myeloid cell development,M001,1,0
0,0,1,0,0,-2.8,GO:0045577,regulation of B cell differentiation,M001,1,0
0,0,1,0,0,-2.1,hsa04721,Synaptic vesicle cycle,M001,1,0
0,1,0,0,-2.8,0,GO:0072522,purine-containing compound biosynthetic process,M010,1,0
1,0,0,-2.6,0,0,GO:0007015,actin filament organization,M100,1,0
0,0,1,0,0,-3.3,GO:0010720,positive regulation of cell development,M001,1,0
1,0,0,-2.2,0,0,GO:0048645,animal organ formation,M100,1,0
0,1,0,0,-2,0,GO:0007156,homophilic cell adhesion via plasma membrane adhesion molecules,M010,1,0
0,0,1,0,0,-2.4,GO:0098976,excitatory chemical synaptic transmission,M001,1,0
0,1,0,0,-3.2,0,GO:0050679,positive regulation of epithelial cell proliferation,M010,1,0
0,0,1,0,0,-2.3,GO:0001764,neuron migration,M001,1,0
0,0,1,0,0,-2.2,GO:0002357,defense response to tumor cell,M001,1,0
0,0,1,0,0,-2,GO:1900006,positive regulation of dendrite development,M001,1,0
1,0,0,-3,0,0,GO:0010544,negative regulation of platelet activation,M100,1,0
1,0,0,-2,0,0,GO:0007406,negative regulation of neuroblast proliferation,M100,1,0
0,1,0,0,-2.2,0,WP5216,Warburg effect modulated by deubiquitinating enzymes and their substrates,M010,1,0
1,0,0,-4,0,0,hsa05206,MicroRNAs in cancer,M100,1,0
0,1,0,0,-2.2,0,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M010,1,0
1,0,0,-4.5,0,0,GO:0042327,positive regulation of phosphorylation,M100,1,0
0,1,0,0,-2.9,0,WP481,Insulin signaling,M010,1,0
1,0,0,-3.8,0,0,GO:0045580,regulation of T cell differentiation,M100,1,0
0,0,1,0,0,-3.8,GO:0046649,lymphocyte activation,M001,1,0
0,1,0,0,-2.8,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M010,1,0
1,0,0,-3.6,0,0,GO:0050863,regulation of T cell activation,M100,1,0
0,0,1,0,0,-2.4,GO:0042471,ear morphogenesis,M001,1,0
1,0,0,-3.6,0,0,WP49,IL 2 signaling pathway,M100,1,0
1,0,0,-2.4,0,0,M8626,SIG BCR SIGNALING PATHWAY,M100,1,0
1,0,0,-3.5,0,0,GO:0090132,epithelium migration,M100,1,0
1,0,0,-2.2,0,0,GO:0002716,negative regulation of natural killer cell mediated immunity,M100,1,0
0,1,0,0,-3.4,0,WP5411,Phosphatidyl inositol phosphate pathway,M010,1,0
1,0,0,-2.2,0,0,GO:0002709,regulation of T cell mediated immunity,M100,1,0
1,0,0,-3.3,0,0,hsa05161,Hepatitis B,M100,1,0
1,0,0,-3.9,0,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-2.7,0,0,GO:0002483,antigen processing and presentation of endogenous peptide antigen,M100,1,0
1,0,0,-4.2,0,0,GO:0040017,positive regulation of locomotion,M100,1,0
1,0,0,-2.7,0,0,M233,PID EPO PATHWAY,M100,1,0
0,0,1,0,0,-2.6,GO:2000648,positive regulation of stem cell proliferation,M001,1,0
1,0,0,-2.8,0,0,GO:0010564,regulation of cell cycle process,M100,1,0
1,0,0,-2.2,0,0,M271,PID PI3K PLC TRK PATHWAY,M100,1,0
0,1,0,0,-3.5,0,hsa05211,Renal cell carcinoma,M010,1,0
1,0,0,-3.1,0,0,R-HSA-9669938,Signaling by KIT in disease,M100,1,0
0,0,1,0,0,-2.1,GO:0002521,leukocyte differentiation,M001,1,0
0,0,1,0,0,-4.1,GO:0007605,sensory perception of sound,M001,1,0
1,0,0,-3,0,0,GO:0055002,striated muscle cell development,M100,1,0
0,1,0,0,-2.7,0,GO:0021529,spinal cord oligodendrocyte cell differentiation,M010,1,0
0,0,1,0,0,-4.5,WP5417,Cell lineage map for neuronal differentiation,M001,1,0
1,0,0,-2.2,0,0,R-HSA-9703465,Signaling by FLT3 fusion proteins,M100,1,0
1,0,0,-2.3,0,0,hsa04540,Gap junction,M100,1,0
0,0,1,0,0,-2.7,GO:1902903,regulation of supramolecular fiber organization,M001,1,0
0,0,1,0,0,-2.1,WP236,Adipogenesis,M001,1,0
0,1,0,0,-2.9,0,GO:2000269,regulation of fibroblast apoptotic process,M010,1,0
0,0,1,0,0,-3.5,GO:0034101,erythrocyte homeostasis,M001,1,0
0,1,0,0,-3.1,0,WP3943,Robo4 and VEGF signaling pathways crosstalk,M010,1,0
0,1,0,0,-2.1,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M010,1,0
0,0,1,0,0,-4.8,GO:0099537,trans-synaptic signaling,M001,1,0
1,0,0,-2.1,0,0,GO:0048511,rhythmic process,M100,1,0
0,1,0,0,-2.3,0,WP673,ErbB signaling pathway,M010,1,0
0,1,0,0,-2.3,0,GO:0030857,negative regulation of epithelial cell differentiation,M010,1,0
0,0,1,0,0,-2.8,GO:0043434,response to peptide hormone,M001,1,0
0,0,1,0,0,-2.4,GO:0003416,endochondral bone growth,M001,1,0
0,1,0,0,-2.2,0,WP2848,Pluripotent stem cell differentiation pathway,M010,1,0
0,1,0,0,-2.4,0,GO:0060509,type I pneumocyte differentiation,M010,1,0
0,0,1,0,0,-2.3,GO:1901989,positive regulation of cell cycle phase transition,M001,1,0
0,0,1,0,0,-2,GO:0009612,response to mechanical stimulus,M001,1,0
1,0,0,-2.1,0,0,GO:1903035,negative regulation of response to wounding,M100,1,0
0,0,1,0,0,-2.1,GO:0051602,response to electrical stimulus,M001,1,0
0,0,1,0,0,-2.3,GO:1901888,regulation of cell junction assembly,M001,1,0
1,0,0,-2.1,0,0,GO:0008406,gonad development,M100,1,0
0,1,0,0,-3.4,0,GO:0048812,neuron projection morphogenesis,M010,1,0
1,0,0,-2.8,0,0,M254,PID MYC REPRESS PATHWAY,M100,1,0
0,0,1,0,0,-2.6,GO:0050804,modulation of chemical synaptic transmission,M001,1,0
0,0,1,0,0,-3.1,GO:0042110,T cell activation,M001,1,0
1,0,0,-2.1,0,0,R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,M100,1,0
1,0,0,-2.4,0,0,GO:0002706,regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.7,0,0,GO:0061438,renal system vasculature morphogenesis,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,M100,1,0
0,1,0,0,-2.7,0,GO:0071679,commissural neuron axon guidance,M010,1,0
1,0,0,-2.3,0,0,GO:0070527,platelet aggregation,M100,1,0
1,0,0,-2.7,0,0,GO:0014911,positive regulation of smooth muscle cell migration,M100,1,0
1,0,0,-2,0,0,R-HSA-9020958,Interleukin-21 signaling,M100,1,0
1,0,0,-2.1,0,0,GO:0010927,cellular component assembly involved in morphogenesis,M100,1,0
0,0,1,0,0,-2.6,GO:0014741,negative regulation of muscle hypertrophy,M001,1,0
0,1,0,0,-2.7,0,GO:0060249,anatomical structure homeostasis,M010,1,0
1,0,0,-2.6,0,0,GO:0009991,response to extracellular stimulus,M100,1,0
0,0,1,0,0,-2.2,GO:0060485,mesenchyme development,M001,1,0
0,1,0,0,-2.2,0,GO:0002067,glandular epithelial cell differentiation,M010,1,0
1,0,0,-2.2,0,0,GO:0055090,acylglycerol homeostasis,M100,1,0
1,0,0,-3,0,0,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M100,1,0
0,1,0,0,-2.9,0,GO:0072224,metanephric glomerulus development,M010,1,0
1,0,0,-2.2,0,0,GO:0010921,regulation of phosphatase activity,M100,1,0
1,0,0,-2.5,0,0,GO:0050878,regulation of body fluid levels,M100,1,0
1,0,0,-2.2,0,0,GO:0061041,regulation of wound healing,M100,1,0
0,0,1,0,0,-2.1,GO:0016444,somatic cell DNA recombination,M001,1,0
0,0,1,0,0,-4.6,GO:0098916,anterograde trans-synaptic signaling,M001,1,0
1,0,0,-2.4,0,0,GO:0016045,detection of bacterium,M100,1,0
0,0,1,0,0,-2.3,GO:0045165,cell fate commitment,M001,1,0
1,0,0,-2.4,0,0,GO:0050819,negative regulation of coagulation,M100,1,0
1,0,0,-2.4,0,0,M135,PID IL5 PATHWAY,M100,1,0
0,1,0,0,-2.2,0,WP2853,Endoderm differentiation,M010,1,0
1,0,0,-4.5,0,0,R-HSA-186763,Downstream signal transduction,M100,1,0
1,0,0,-3.2,0,0,GO:0007405,neuroblast proliferation,M100,1,0
1,0,0,-3.9,0,0,GO:0022409,positive regulation of cell-cell adhesion,M100,1,0
0,0,1,0,0,-3,hsa04724,Glutamatergic synapse,M001,1,0
1,0,0,-2,0,0,GO:0070365,hepatocyte differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0043154,negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,M010,1,0
0,1,0,0,-2.9,0,GO:0060644,mammary gland epithelial cell differentiation,M010,1,0
1,0,0,-3.2,0,0,GO:0043549,regulation of kinase activity,M100,1,0
1,0,0,-3.1,0,0,GO:0070669,response to interleukin-2,M100,1,0
0,0,1,0,0,-2.2,GO:1905145,cellular response to acetylcholine,M001,1,0
0,1,0,0,-2.7,0,GO:0060479,lung cell differentiation,M010,1,0
1,0,0,-2.4,0,0,WP3972,PDGFR beta pathway,M100,1,0
0,0,1,0,0,-2.4,GO:0043583,ear development,M001,1,0
0,1,0,0,-2.4,0,R-HSA-197264,Nicotinamide salvaging,M010,1,0
0,1,0,0,-2,0,GO:0002467,germinal center formation,M010,1,0
0,1,0,0,-2.1,0,R-HSA-1660499,Synthesis of PIPs at the plasma membrane,M010,1,0
0,1,0,0,-2.1,0,GO:1903053,regulation of extracellular matrix organization,M010,1,0
0,0,1,0,0,-2.3,GO:0048738,cardiac muscle tissue development,M001,1,0
0,0,1,0,0,-2.4,GO:1902532,negative regulation of intracellular signal transduction,M001,1,0
0,0,1,0,0,-2.5,GO:0003007,heart morphogenesis,M001,1,0
0,0,1,0,0,-2.3,GO:0072132,mesenchyme morphogenesis,M001,1,0
0,1,0,0,-5,0,GO:0030855,epithelial cell differentiation,M010,1,0
0,0,1,0,0,-2.8,GO:0031214,biomineral tissue development,M001,1,0
1,0,0,-2.7,0,0,GO:0010800,positive regulation of peptidyl-threonine phosphorylation,M100,1,0
1,0,0,-2.6,0,0,GO:0071396,cellular response to lipid,M100,1,0
1,0,0,-2.3,0,0,hsa04722,Neurotrophin signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0099171,presynaptic modulation of chemical synaptic transmission,M100,1,0
0,1,0,0,-2.2,0,R-HSA-432722,Golgi Associated Vesicle Biogenesis,M010,1,0
0,0,1,0,0,-3.1,GO:0050871,positive regulation of B cell activation,M001,1,0
1,0,0,-3.8,0,0,GO:0031032,actomyosin structure organization,M100,1,0
1,0,0,-3.1,0,0,GO:0048009,insulin-like growth factor receptor signaling pathway,M100,1,0
1,0,0,-2.7,0,0,GO:2000379,positive regulation of reactive oxygen species metabolic process,M100,1,0
0,1,0,0,-2.1,0,WP4559,Interactions between immune cells and microRNAs in tumor microenvironment,M010,1,0
0,1,0,0,-4.7,0,GO:0045765,regulation of angiogenesis,M010,1,0
1,0,0,-3.4,0,0,M91,PID TCPTP PATHWAY,M100,1,0
1,0,0,-4.7,0,0,hsa05223,Non-small cell lung cancer,M100,1,0
0,1,0,0,-2.2,0,GO:0097475,motor neuron migration,M010,1,0
1,0,0,-2.3,0,0,GO:0001667,ameboidal-type cell migration,M100,1,0
1,0,0,-5.1,0,0,GO:0010634,positive regulation of epithelial cell migration,M100,1,0
0,0,1,0,0,-2.5,GO:0001503,ossification,M001,1,0
0,0,1,0,0,-2.3,GO:0034330,cell junction organization,M001,1,0
1,0,0,-3.7,0,0,GO:0006470,protein dephosphorylation,M100,1,0
1,0,0,-2.2,0,0,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M100,1,0
0,1,0,0,-4.3,0,GO:2000629,negative regulation of miRNA metabolic process,M010,1,0
0,1,0,0,-2,0,GO:0048015,phosphatidylinositol-mediated signaling,M010,1,0
0,1,0,0,-2.1,0,GO:0050886,endocrine process,M010,1,0
0,0,1,0,0,-2.1,GO:0021987,cerebral cortex development,M001,1,0
0,1,0,0,-2.1,0,GO:0002279,mast cell activation involved in immune response,M010,1,0
0,1,0,0,-2.1,0,GO:0070201,regulation of establishment of protein localization,M010,1,0
0,1,0,0,-2.5,0,WP4971,Phosphoinositides metabolism,M010,1,0
0,0,1,0,0,-2.8,GO:0043065,positive regulation of apoptotic process,M001,1,0
0,1,0,0,-2.7,0,GO:1902170,cellular response to reactive nitrogen species,M010,1,0
1,0,0,-2.1,0,0,GO:0055006,cardiac cell development,M100,1,0
1,0,0,-2.4,0,0,GO:0050688,regulation of defense response to virus,M100,1,0
1,0,0,-2.4,0,0,GO:0070663,regulation of leukocyte proliferation,M100,1,0
1,0,0,-5.1,0,0,M143,PID IL2 PI3K PATHWAY,M100,1,0
0,0,1,0,0,-2.9,GO:0003203,endocardial cushion morphogenesis,M001,1,0
0,0,1,0,0,-2.2,GO:0035108,limb morphogenesis,M001,1,0
0,0,1,0,0,-2.4,GO:0048871,multicellular organismal-level homeostasis,M001,1,0
1,0,0,-2.3,0,0,GO:0002823,negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
1,0,0,-2.2,0,0,R-HSA-109582,Hemostasis,M100,1,0
0,1,0,0,-2,0,GO:0030177,positive regulation of Wnt signaling pathway,M010,1,0
0,0,1,0,0,-2.1,GO:0008285,negative regulation of cell population proliferation,M001,1,0
1,0,0,-2.1,0,0,hsa05163,Human cytomegalovirus infection,M100,1,0
1,0,0,-2.7,0,0,GO:0010543,regulation of platelet activation,M100,1,0
0,1,0,0,-2.2,0,GO:0045602,negative regulation of endothelial cell differentiation,M010,1,0
1,0,0,-2.3,0,0,GO:0050853,B cell receptor signaling pathway,M100,1,0
0,1,0,0,-2.2,0,M193,PID NEPHRIN NEPH1 PATHWAY,M010,1,0
1,0,0,-2.5,0,0,GO:0050670,regulation of lymphocyte proliferation,M100,1,0
1,0,0,-3.3,0,0,GO:0050778,positive regulation of immune response,M100,1,0
1,0,0,-2,0,0,GO:0007548,sex differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:0044772,mitotic cell cycle phase transition,M100,1,0
0,1,0,0,-2.7,0,GO:0002444,myeloid leukocyte mediated immunity,M010,1,0
0,0,1,0,0,-2.2,GO:0095500,acetylcholine receptor signaling pathway,M001,1,0
1,0,0,-2.3,0,0,GO:1903047,mitotic cell cycle process,M100,1,0
1,0,0,-2.7,0,0,GO:0031343,positive regulation of cell killing,M100,1,0
1,0,0,-3.9,0,0,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M100,1,0
1,0,0,-3.4,0,0,GO:0055003,cardiac myofibril assembly,M100,1,0
1,0,0,-3,0,0,GO:1902105,regulation of leukocyte differentiation,M100,1,0
1,0,0,-2.8,0,0,GO:0002819,regulation of adaptive immune response,M100,1,0
1,0,0,-2,0,0,GO:0007163,establishment or maintenance of cell polarity,M100,1,0
0,1,0,0,-2.2,0,GO:0061180,mammary gland epithelium development,M010,1,0
0,1,0,0,-2.6,0,M185,PID ALK1 PATHWAY,M010,1,0
0,0,1,0,0,-2.8,GO:0043433,negative regulation of DNA-binding transcription factor activity,M001,1,0
0,0,1,0,0,-2,WP437,EGF EGFR signaling pathway,M001,1,0
1,0,0,-4,0,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-2.7,0,0,GO:0000278,mitotic cell cycle,M100,1,0
1,0,0,-3,0,0,M50,PID PTP1B PATHWAY,M100,1,0
1,0,0,-2.3,0,0,M66,PID MYC ACTIV PATHWAY,M100,1,0
0,0,1,0,0,-2.3,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M001,1,0
0,1,0,0,-3.5,0,GO:0097485,neuron projection guidance,M010,1,0
0,1,0,0,-2.3,0,WP4659,Gastrin signaling pathway,M010,1,0
1,0,0,-2,0,0,R-HSA-417957,P2Y receptors,M100,1,0
0,1,0,0,-2,0,GO:0110011,regulation of basement membrane organization,M010,1,0
1,0,0,-3,0,0,GO:0002820,negative regulation of adaptive immune response,M100,1,0
1,0,0,-2.1,0,0,hsa04066,HIF-1 signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0032680,regulation of tumor necrosis factor production,M100,1,0
0,1,0,0,-2,0,GO:0030879,mammary gland development,M010,1,0
1,0,0,-3.8,0,0,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0003300,cardiac muscle hypertrophy,M010,1,0
1,0,0,-2.2,0,0,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M100,1,0
0,0,1,0,0,-2,GO:0046631,alpha-beta T cell activation,M001,1,0
0,1,0,0,-2.4,0,GO:0003301,physiological cardiac muscle hypertrophy,M010,1,0
0,0,1,0,0,-2.4,GO:0061052,negative regulation of cell growth involved in cardiac muscle cell development,M001,1,0
1,0,0,-2.4,0,0,GO:0001779,natural killer cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0006468,protein phosphorylation,M100,1,0
1,0,0,-2.2,0,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M100,1,0
0,0,1,0,0,-2.4,GO:0048706,embryonic skeletal system development,M001,1,0
0,0,1,0,0,-2,GO:0035988,chondrocyte proliferation,M001,1,0
1,0,0,-2.9,0,0,GO:0043666,regulation of phosphoprotein phosphatase activity,M100,1,0
1,0,0,-3.1,0,0,GO:0001787,natural killer cell proliferation,M100,1,0
0,0,1,0,0,-5.6,GO:0099536,synaptic signaling,M001,1,0
1,0,0,-2.4,0,0,GO:0072012,glomerulus vasculature development,M100,1,0
0,0,1,0,0,-3.7,GO:0045321,leukocyte activation,M001,1,0
1,0,0,-2.3,0,0,GO:0042472,inner ear morphogenesis,M100,1,0
1,0,0,-2.5,0,0,GO:0006914,autophagy,M100,1,0
0,0,1,0,0,-2.6,WP4541,Hippo Merlin signaling dysregulation,M001,1,0
0,0,1,0,0,-2.1,GO:0045662,negative regulation of myoblast differentiation,M001,1,0
0,0,1,0,0,-2,GO:0002829,negative regulation of type 2 immune response,M001,1,0
0,0,1,0,0,-2.1,GO:0002562,somatic diversification of immune receptors via germline recombination within a single locus,M001,1,0
0,0,1,0,0,-7.5,GO:0001501,skeletal system development,M001,1,0
0,1,0,0,-2.5,0,GO:0006979,response to oxidative stress,M010,1,0
0,0,1,0,0,-3.4,GO:1901652,response to peptide,M001,1,0
1,0,0,-2.5,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-3.6,0,0,GO:0098581,detection of external biotic stimulus,M100,1,0
0,0,1,0,0,-4.2,GO:0051965,positive regulation of synapse assembly,M001,1,0
0,0,1,0,0,-2.2,GO:0014743,regulation of muscle hypertrophy,M001,1,0
1,0,0,-2.8,0,0,GO:0032944,regulation of mononuclear cell proliferation,M100,1,0
0,0,1,0,0,-2.3,GO:0010863,positive regulation of phospholipase C activity,M001,1,0
1,0,0,-2,0,0,hsa04115,p53 signaling pathway,M100,1,0
0,0,1,0,0,-3.8,GO:0030218,erythrocyte differentiation,M001,1,0
0,1,0,0,-3.7,0,WP4674,Head and neck squamous cell carcinoma,M010,1,0
0,0,1,0,0,-2.9,GO:1903131,mononuclear cell differentiation,M001,1,0
1,0,0,-2.7,0,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
1,0,0,-3.4,0,0,R-HSA-451927,Interleukin-2 family signaling,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M100,1,0
1,0,0,-3.3,0,0,GO:0042129,regulation of T cell proliferation,M100,1,0
1,0,0,-2.2,0,0,GO:0009617,response to bacterium,M100,1,0
0,1,0,0,-2.3,0,GO:0045913,positive regulation of carbohydrate metabolic process,M010,1,0
1,0,0,-2.8,0,0,GO:0007264,small GTPase mediated signal transduction,M100,1,0
1,0,0,-4.8,0,0,R-HSA-8983432,Interleukin-15 signaling,M100,1,0
1,0,0,-2.4,0,0,GO:0072102,glomerulus morphogenesis,M100,1,0
0,0,1,0,0,-2.4,GO:0030099,myeloid cell differentiation,M001,1,0
1,0,0,-2,0,0,WP530,Cytokines and inflammatory response,M100,1,0
1,0,0,-2.4,0,0,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-4.6,0,0,WP4255,Non small cell lung cancer,M100,1,0
1,0,0,-2.7,0,0,WP322,Osteoblast signaling,M100,1,0
0,0,1,0,0,-3,GO:0014706,striated muscle tissue development,M001,1,0
0,1,0,0,-3.8,0,hsa04216,Ferroptosis,M010,1,0
0,0,1,0,0,-2.2,GO:0015813,L-glutamate transmembrane transport,M001,1,0
0,0,1,0,0,-2.7,GO:0071375,cellular response to peptide hormone stimulus,M001,1,0
1,0,0,-2.3,0,0,GO:0061440,kidney vasculature development,M100,1,0
1,0,0,-4.6,0,0,GO:0030335,positive regulation of cell migration,M100,1,0
0,1,0,0,-2.4,0,GO:0010563,negative regulation of phosphorus metabolic process,M010,1,0
1,0,0,-2.8,0,0,WP170,Nuclear receptors,M100,1,0
0,1,0,0,-3.5,0,GO:0007411,axon guidance,M010,1,0
0,0,1,0,0,-2.2,GO:0051154,negative regulation of striated muscle cell differentiation,M001,1,0
1,0,0,-2.1,0,0,WP4666,Hepatitis B infection,M100,1,0
1,0,0,-3.4,0,0,WP3981,miRNA regulation of prostate cancer signaling pathways,M100,1,0
0,1,0,0,-2,0,R-HSA-196807,Nicotinate metabolism,M010,1,0
0,1,0,0,-3.5,0,GO:1903670,regulation of sprouting angiogenesis,M010,1,0
0,0,1,0,0,-3.1,GO:0002637,regulation of immunoglobulin production,M001,1,0
1,0,0,-2.6,0,0,R-HSA-1433557,Signaling by SCF-KIT,M100,1,0
1,0,0,-2.3,0,0,WP4758,Nephrotic syndrome,M100,1,0
0,0,1,0,0,-2.2,GO:0098868,bone growth,M001,1,0
0,0,1,0,0,-2.3,GO:0007265,Ras protein signal transduction,M001,1,0
1,0,0,-2.4,0,0,R-HSA-202131,Metabolism of nitric oxide: NOS3 activation and regulation,M100,1,0
1,0,0,-2.1,0,0,GO:0031668,cellular response to extracellular stimulus,M100,1,0
1,0,0,-3,0,0,WP127,IL 5 signaling pathway,M100,1,0
0,0,1,0,0,-3,GO:1901992,positive regulation of mitotic cell cycle phase transition,M001,1,0
1,0,0,-2.5,0,0,GO:0046651,lymphocyte proliferation,M100,1,0
0,0,1,0,0,-2.6,GO:0099177,regulation of trans-synaptic signaling,M001,1,0
0,0,1,0,0,-2.1,GO:0043516,"regulation of DNA damage response, signal transduction by p53 class mediator",M001,1,0
0,0,1,0,0,-2,GO:0045664,regulation of neuron differentiation,M001,1,0
1,0,0,-3.9,0,0,GO:0050870,positive regulation of T cell activation,M100,1,0
1,0,0,-5.8,0,0,GO:0010595,positive regulation of endothelial cell migration,M100,1,0
0,0,1,0,0,-2.3,GO:0071345,cellular response to cytokine stimulus,M001,1,0
1,0,0,-5.6,0,0,GO:0010562,positive regulation of phosphorus metabolic process,M100,1,0
0,0,1,0,0,-2.2,GO:0070486,leukocyte aggregation,M001,1,0
0,1,0,0,-2.2,0,GO:0090630,activation of GTPase activity,M010,1,0
1,0,0,-2.8,0,0,WP306,Focal adhesion,M100,1,0
0,0,1,0,0,-4.2,GO:0010517,regulation of phospholipase activity,M001,1,0
0,1,0,0,-2.6,0,hsa04380,Osteoclast differentiation,M010,1,0
1,0,0,-2.4,0,0,GO:0050817,coagulation,M100,1,0
1,0,0,-2.4,0,0,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M100,1,0
0,1,0,0,-2.2,0,GO:0051149,positive regulation of muscle cell differentiation,M010,1,0
0,1,0,0,-2.3,0,WP2882,Nuclear receptors meta pathway,M010,1,0
0,1,0,0,-3.5,0,GO:0048667,cell morphogenesis involved in neuron differentiation,M010,1,0
1,0,0,-2.2,0,0,GO:0007599,hemostasis,M100,1,0
0,1,0,0,-2,0,M158,PID INTEGRIN4 PATHWAY,M010,1,0
0,1,0,0,-3,0,GO:0006164,purine nucleotide biosynthetic process,M010,1,0
1,0,0,-2.9,0,0,GO:0042060,wound healing,M100,1,0
0,0,1,0,0,-2.6,WP4540,Hippo signaling regulation pathways,M001,1,0
1,0,0,-2,0,0,GO:0071378,cellular response to growth hormone stimulus,M100,1,0
0,0,1,0,0,-2.3,GO:0010611,regulation of cardiac muscle hypertrophy,M001,1,0
0,0,1,0,0,-2,GO:0045471,response to ethanol,M001,1,0
1,0,0,-2.5,0,0,GO:0031348,negative regulation of defense response,M100,1,0
1,0,0,-3.4,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9645135,STAT5 Activation,M100,1,0
1,0,0,-3,0,0,GO:0030239,myofibril assembly,M100,1,0
0,1,0,0,-3.4,0,GO:0120039,plasma membrane bounded cell projection morphogenesis,M010,1,0
1,0,0,-2.2,0,0,WP4585,Cancer immunotherapy by PD 1 blockade,M100,1,0
0,1,0,0,-2.1,0,GO:0042326,negative regulation of phosphorylation,M010,1,0
0,0,1,0,0,-2.3,GO:0032868,response to insulin,M001,1,0
1,0,0,-2.7,0,0,GO:0061439,kidney vasculature morphogenesis,M100,1,0
0,1,0,0,-3.7,0,WP4149,White fat cell differentiation,M010,1,0
1,0,0,-2.2,0,0,GO:0010659,cardiac muscle cell apoptotic process,M100,1,0
0,1,0,0,-3.4,0,GO:0061564,axon development,M010,1,0
0,1,0,0,-2.2,0,GO:0060428,lung epithelium development,M010,1,0
0,1,0,0,-2.2,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M010,1,0
1,0,0,-2.4,0,0,GO:0042269,regulation of natural killer cell mediated cytotoxicity,M100,1,0
1,0,0,-2.4,0,0,GO:0090257,regulation of muscle system process,M100,1,0
1,0,0,-3.4,0,0,GO:0070672,response to interleukin-15,M100,1,0
1,0,0,-2.5,0,0,hsa05222,Small cell lung cancer,M100,1,0
0,0,1,0,0,-2.4,GO:0043068,positive regulation of programmed cell death,M001,1,0
1,0,0,-2.2,0,0,WP3584,MECP2 and associated Rett syndrome,M100,1,0
1,0,0,-2.7,0,0,hsa01521,EGFR tyrosine kinase inhibitor resistance,M100,1,0
0,1,0,0,-2.7,0,GO:0001894,tissue homeostasis,M010,1,0
1,0,0,-2.3,0,0,GO:0031667,response to nutrient levels,M100,1,0
1,0,0,-3.6,0,0,GO:0001916,positive regulation of T cell mediated cytotoxicity,M100,1,0
1,0,0,-4.2,0,0,GO:0045785,positive regulation of cell adhesion,M100,1,0
1,0,0,-2.4,0,0,GO:0045953,negative regulation of natural killer cell mediated cytotoxicity,M100,1,0
1,0,0,-2.5,0,0,GO:0043536,positive regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-3.2,0,0,R-HSA-186797,Signaling by PDGF,M100,1,0
0,0,1,0,0,-2.8,WP5198,Inflammatory bowel disease signaling,M001,1,0
0,0,1,0,0,-2.9,R-HSA-9031628,NGF-stimulated transcription,M001,1,0
1,0,0,-2.1,0,0,GO:0072006,nephron development,M100,1,0
1,0,0,-2.8,0,0,M162,PID RXR VDR PATHWAY,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9702518,STAT5 activation downstream of FLT3 ITD mutants,M100,1,0
0,1,0,0,-2.8,0,WP3931,Embryonic stem cell pluripotency pathways,M010,1,0
0,0,1,0,0,-2.3,GO:0071772,response to BMP,M001,1,0
1,0,0,-2.5,0,0,GO:0009595,detection of biotic stimulus,M100,1,0
1,0,0,-3.6,0,0,GO:0010631,epithelial cell migration,M100,1,0
1,0,0,-2.2,0,0,GO:0046635,positive regulation of alpha-beta T cell activation,M100,1,0
0,0,1,0,0,-2.6,GO:0007193,adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway,M001,1,0
0,1,0,0,-2.5,0,GO:0090407,organophosphate biosynthetic process,M010,1,0
1,0,0,-2.3,0,0,WP5090,Complement system in neuronal development and plasticity,M100,1,0
0,0,1,0,0,-2.4,GO:0046321,positive regulation of fatty acid oxidation,M001,1,0
0,0,1,0,0,-2.1,GO:1904752,regulation of vascular associated smooth muscle cell migration,M001,1,0
0,0,1,0,0,-2.9,GO:0030326,embryonic limb morphogenesis,M001,1,0
0,1,0,0,-3.4,0,GO:0030900,forebrain development,M010,1,0
0,0,1,0,0,-3.4,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M001,1,0
1,0,0,-2.3,0,0,GO:0016311,dephosphorylation,M100,1,0
0,1,0,0,-2.5,0,GO:1901293,nucleoside phosphate biosynthetic process,M010,1,0
0,0,1,0,0,-3.3,GO:0044089,positive regulation of cellular component biogenesis,M001,1,0
1,0,0,-3.7,0,0,WP5098,T cell activation SARS CoV 2,M100,1,0
0,0,1,0,0,-2.1,GO:0002700,regulation of production of molecular mediator of immune response,M001,1,0
0,1,0,0,-2,0,GO:1903671,negative regulation of sprouting angiogenesis,M010,1,0
0,0,1,0,0,-2,GO:0034114,regulation of heterotypic cell-cell adhesion,M001,1,0
1,0,0,-3.4,0,0,R-HSA-1280215,Cytokine Signaling in Immune system,M100,1,0
1,0,0,-2.1,0,0,GO:0070059,intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,M100,1,0
1,0,0,-4.7,0,0,GO:0001914,regulation of T cell mediated cytotoxicity,M100,1,0
1,0,0,-3.7,0,0,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M100,1,0
1,0,0,-2.4,0,0,hsa05226,Gastric cancer,M100,1,0
0,1,0,0,-2.6,0,GO:0048588,developmental cell growth,M010,1,0
1,0,0,-2.3,0,0,GO:0034109,homotypic cell-cell adhesion,M100,1,0
0,1,0,0,-2.6,0,WP4313,Ferroptosis,M010,1,0
0,0,1,0,0,-2.2,GO:1904754,positive regulation of vascular associated smooth muscle cell migration,M001,1,0
1,0,0,-2.2,0,0,M13,PID ERBB4 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0014910,regulation of smooth muscle cell migration,M100,1,0
1,0,0,-2.1,0,0,M115,PID REG GR PATHWAY,M100,1,0
1,0,0,-2.2,0,0,R-HSA-1236394,Signaling by ERBB4,M100,1,0
0,0,1,0,0,-2.1,GO:0034340,response to type I interferon,M001,1,0
1,0,0,-2.3,0,0,hsa05169,Epstein-Barr virus infection,M100,1,0
0,0,1,0,0,-2.7,GO:0042474,middle ear morphogenesis,M001,1,0
0,1,0,0,-2.3,0,hsa00562,Inositol phosphate metabolism,M010,1,0
1,0,0,-3.8,0,0,M234,PID IL2 STAT5 PATHWAY,M100,1,0
1,0,0,-2.7,0,0,hsa04917,Prolactin signaling pathway,M100,1,0
0,0,1,0,0,-2.8,GO:0044057,regulation of system process,M001,1,0
0,1,0,0,-2.5,0,R-HSA-9006335,Signaling by Erythropoietin,M010,1,0
1,0,0,-3.2,0,0,GO:0051338,regulation of transferase activity,M100,1,0
0,1,0,0,-2.3,0,GO:0006109,regulation of carbohydrate metabolic process,M010,1,0
0,1,0,0,-2.3,0,hsa04919,Thyroid hormone signaling pathway,M010,1,0
1,0,0,-2.5,0,0,GO:0019883,antigen processing and presentation of endogenous antigen,M100,1,0
